TGX-221 is primarily used in research settings as a selective inhibitor of the PI3Kβ (phosphoinositide 3-kinase beta) isoform. It is a valuable tool for studying the role of PI3Kβ in various cellular processes, particularly in signaling pathways related to cell growth, survival, and metabolism. Researchers utilize TGX-221 to investigate its effects on cancer biology, as PI3Kβ is often implicated in tumor progression and resistance to therapies. Additionally, it is employed in studies exploring cardiovascular diseases, where PI3Kβ signaling plays a role in platelet activation and thrombosis. By selectively inhibiting PI3Kβ, TGX-221 helps elucidate its specific contributions to these pathways, aiding in the development of targeted therapeutic strategies.